Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 6:03 AM EDT-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million
-81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse
-Company to Host Quarterly Conference Call at 8:30 am ET Today
CORAL GABLES, Fla., May 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results... More
